BRAF and cutaneous melanoma: Cutaneous melanoma frequently harbors activating mutations in NRAS (around 20%) or the RAS-regulated kinase BRAF (around 37%), suggesting that the RAS-RAF-MAPK pathway may be critical in the pathogenesis of cutaneous melanoma [12–14].